Spinouts always operate, by their very nature, on the cutting edge of science, but every once in a while, one comes along that could prove truly transformational by inventing an entirely new field.
Evox Therapeutics, which exploits research from University of Oxford and Karolinska Institute, is one of these: the spinout is a pioneer in the exosome therapeutics space – a new class of therapeutics that Evox is initially aiming at rare metabolic conditions but that has applications far beyond these target areas. Evox, established in 2016, is…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.